Save over 60% on brand Pomalyst (called Imnovid in Europe) or 95% with generic Pomalyst.
Click here for information on Natco generics (Immediate availability)
Brand version from Europe: Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.
According to the European Medicines Agency, brand name Imnovid originating from Europe is manufactured at the following site(s):Celgene Distribution B.V.
Orteliuslaan 1000
3528 BD Utrecht
Netherlands
Information about Pomalyst (Pomalidomide)
Pomalyst (Pomalidomide) is a medication primarily used in the treatment of multiple myeloma, a type of blood cancer. It is a thalidomide analogue that works by modulating the immune system to inhibit the growth of cancerous cells and disrupts the tumor microenvironment. Pomalyst is used in combination with other therapies, often as part of a broader treatment regimen for patients who have not responded well to other therapies.
Product Highlights
- Pomalyst is most commonly used for treating multiple myeloma in patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have shown disease progression.
- In some cases, pomalidomide may be used for patients with Kaposi's sarcoma, especially in those who are HIV-positive.
Key Ingredient
Key Benefits
- It has shown effectiveness in patients whose disease has not responded to other treatments, like lenalidomide.
- It is taken as a pill, making it more convenient than some intravenous cancer treatments.
- It has been shown to improve progression-free survival in combination with other agents, like dexamethasone.
Directions for Use
- The typical recommended dosage is 4 mg per day, taken orally once daily, for 21 days of a 28-day treatment cycle.
- Pomalyst should typically be taken on an empty stomach, either 1 hour before or 2 hours after eating.
- If a dose is missed, patients should take it as soon as possible on the same day, unless it is almost time for the next dose, in which case the missed dose should be skipped. Double dosing should be avoided.
Safety Concerns
- Pomalyst can increase the risk of blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE), especially when combined with other therapies like dexamethasone.
- Pomalyst is highly teratogenic (causes birth defects), and it should never be used during pregnancy. Women of childbearing potential must use reliable contraception during treatment and for 4 weeks after stopping treatment.
- It can cause significant blood-related side effects, such as neutropenia, anemia, and thrombocytopenia. Regular blood monitoring is required.
- As an immunosuppressant, Pomalyst may increase the risk of infections, including pneumonia.
- Liver function should be monitored during treatment, as Pomalyst can cause elevated liver enzymes.
Avoid Pomalyst (Pomalidomide) If
- Pomalyst should not be used in pregnant women, as it may cause severe birth defects or fetal death. It is classified as a Category X drug for use during pregnancy.
- Patients who have a known allergy to pomalidomide or thalidomide should avoid using this drug.
- Pomalyst should be used with caution or avoided in patients with severe liver impairment due to the increased risk of liver toxicity.
- If a patient has a history of severe bone marrow suppression (e.g., severe neutropenia, thrombocytopenia, or anemia), the drug may be contraindicated.
- Pomalyst should not be used in patients with active or uncontrolled infections due to its immunosuppressive effects.
